Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of B cell malignancies, yet its application in T cell malignancies remains challenging due to issues such as fratricide and the risk of graft-versus-host disease (GvHD). My research focuses on overcoming these barriers by developing “off-the-shelf” CAR-T cell therapies for T cell leukemias and lymphomas. Leveraging advanced CRISPR-based gene editing technologies, we aim to engineer allogeneic T cells with enhanced safety and efficacy profiles. This includes novel strategies to eliminate endogenous TCR and shared target antigens while preserving anti-tumor activity, with the goal of making scalable, universal CAR-T cell products for clinical application.